SCHEMBL21900482

SCHEMBL21900482

CC(C)(C)OC(=O)N[C@@H]1CCCN(c2c(F)cc(Br)cc2F)C1=O

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 11/20 0.41
F10 P00742 2/20 0.40
F2 P00734 1/20 0.40
PRSS1 P07477 1/20 0.40
FPR1 P21462 4/20 0.40
GAA P10253 1/20 0.37
USP30 Q70CQ3 1/20 0.37
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
ALOX5AP P20292 1/20 0.35
FEN1 P39748 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28376667 1.00 FPR2 (0.41) FPR2F10F2PRSS1FPR1
SCHEMBL8302296 0.93 FPR2 (0.40) FPR2FPR1GAAUSP30NFKB1
SCHEMBL23168328 0.86 F10 (0.46) FPR2F10FPR1USP30
SCHEMBL23168331 0.86 F10 (0.46) FPR2F10FPR1USP30
SCHEMBL20581794 0.83 FPR2 (0.42) FPR2FPR1
SCHEMBL20581795 0.83 FPR2 (0.42) FPR2FPR1
SCHEMBL8299289 0.81 FPR2 (0.40) FPR2F10F2PRSS1FPR1
SCHEMBL18963926 0.81 FPR2 (0.48) FPR2F10F2PRSS1FPR1
SCHEMBL18963928 0.81 FPR2 (0.48) FPR2F10F2PRSS1FPR1
SCHEMBL8300928 0.80 FPR1 (0.39) FPR2FPR1GAANFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114008059-B Biaryl dialkylphosphine oxide FPR2 agonists 百时美施贵宝公司 2024-03-12 CN disclosed
EP-3986903-B1 BIARYL DIALKYL PHOSPHINE OXIDE FPR2 AGONISTS BRISTOL MYERS SQUIBB CO (US) 2023-05-10 EP disclosed
EP-3986903-B1 BIARYL DIALKYL PHOSPHINE OXIDE FPR2 AGONISTS BRISTOL MYERS SQUIBB CO (US) 2023-05-10 EP disclosed
CN-110996950-B Piperidinone formyl peptide 2 receptor agonists and formyl peptide 1 receptor agonists 百时美施贵宝公司 2023-04-04 CN disclosed
US-20220298186-A1 BIARYL DIALKYL PHOSPHINE OXIDE FPR2 AGONISTS BRISTOL MYERS SQUIBB CO (US) 2022-09-22 US disclosed
EP-3986903-A1 BIARYL DIALKYL PHOSPHINE OXIDE FPR2 AGONISTS Bristol-Myers Squibb Company (US) 2022-04-27 EP disclosed
CN-114008059-A Biaryl dialkylphosphine oxide FPR2 agonists 百时美施贵宝公司 2022-02-01 CN disclosed
US-11186544-B2 Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists BRISTOL-MYERS SQUIBB COMPANY (US) 2021-11-30 US disclosed
WO-2020257161-A1 BIARYL DIALKYL PHOSPHINE OXIDE FPR2 AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2020-12-24 WO disclosed
US-20200123108-A1 PIPERIDINONE FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS BRISTOL MYERS SQUIBB CO (US) 2020-04-23 US disclosed
CN-110996950-A Piperidinone formyl peptide 2 receptor agonists and formyl peptide 1 receptor agonists 百时美施贵宝公司 2020-04-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11186544-B2 Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists FPR1, FPR2, FPR3 FPR2 2/4885F10 2461/4885F2 309/4885
US-20200123108-A1 PIPERIDINONE FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS FPR1, FPR2, FPR3 FPR2 2/4885F10 2461/4885F2 309/4885
US-20220298186-A1 BIARYL DIALKYL PHOSPHINE OXIDE FPR2 AGONISTS FPR1, FPR2, FPR3 FPR2 2/4885F10 2537/4885F2 193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.